Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer
نویسندگان
چکیده
منابع مشابه
Clinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملAn unusual metastatic breast cancer presentation Report of a case
ABSTRACTWe are reporting a 43-year-old female breast cancer case with a solitary metastatic adenocarcinoma in clivus. This patient with a stage II (T1N1M0) breast cancer history has been followed for 7 years. Modified Radical Mastectomy (MRM) and 6 courses chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5FU) regimen were done for her at the time of diagnosis. Also, she took tamoxifen tw...
متن کاملclincopathological features of non-metastatic triple negative breast cancer
background: triple negative breast cancer (tnbc) is reported to be associated with a high risk of recurrence, poor overall survival (os), and disease-free survival (dfs) rates. this study evaluated the clincopathological features and survival of non-metastatic tnbc women in the capital of iran compared with other areas of the world. methods: in a retrospective study, 119 women with tnbc based o...
متن کاملReview of docetaxel/doxorubicin combination in metastatic breast cancer.
Docetaxel (Taxotere) and doxorubicin (Adriamycin) have each demonstrated significant activity in metastatic breast cancer. Thus, the combination of docetaxel and doxorubicin has been evaluated in phase I trials to establish the dose-limiting toxicity, maximum tolerated dose, recommended dose for future phase II and III studies, and toxicity profile of the two agents used in combination. Results...
متن کاملDocetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for patients with metastatic breast cancer. The maximum tolerated dose of this combination was 50 mg/m2 of doxorubicin given as an intravenous bolus followed 1 hour later with 75 mg/m2 of docetaxel given as a 1-hour intraveno...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ACS Omega
سال: 2021
ISSN: 2470-1343,2470-1343
DOI: 10.1021/acsomega.0c05350